ROMJF
Price
$0.44
Change
-$0.02 (-4.35%)
Updated
Sep 5 closing price
Capitalization
28.73M
RSCI
Price
$0.07
Change
-$0.10 (-58.82%)
Updated
May 13 closing price
Capitalization
14.29M
Interact to see
Advertisement

ROMJF vs RSCI

Header iconROMJF vs RSCI Comparison
Open Charts ROMJF vs RSCIBanner chart's image
Rubicon Organics
Price$0.44
Change-$0.02 (-4.35%)
Volume$24.6K
Capitalization28.73M
Redwood Scientific Technologies
Price$0.07
Change-$0.10 (-58.82%)
Volume$13.39K
Capitalization14.29M
ROMJF vs RSCI Comparison Chart in %
Loading...
ROMJF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ROMJF vs. RSCI commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ROMJF is a Hold and RSCI is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (ROMJF: $0.44 vs. RSCI: $0.07)
Brand notoriety: ROMJF and RSCI are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ROMJF: 51% vs. RSCI: 100%
Market capitalization -- ROMJF: $28.73M vs. RSCI: $14.29M
ROMJF [@Pharmaceuticals: Generic] is valued at $28.73M. RSCI’s [@Pharmaceuticals: Generic] market capitalization is $14.29M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.94B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ROMJF’s FA Score shows that 0 FA rating(s) are green whileRSCI’s FA Score has 0 green FA rating(s).

  • ROMJF’s FA Score: 0 green, 5 red.
  • RSCI’s FA Score: 0 green, 5 red.
According to our system of comparison, ROMJF is a better buy in the long-term than RSCI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ROMJF’s TA Score shows that 2 TA indicator(s) are bullish.

  • ROMJF’s TA Score: 2 bullish, 5 bearish.

Price Growth

ROMJF (@Pharmaceuticals: Generic) experienced а -9.76% price change this week, while RSCI (@Pharmaceuticals: Generic) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.10%. For the same industry, the average monthly price growth was +12.13%, and the average quarterly price growth was +87.01%.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.10% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ROMJF($28.7M) has a higher market cap than RSCI($14.3M). ROMJF YTD gains are higher at: 34.016 vs. RSCI (-32.432). ROMJF has higher annual earnings (EBITDA): 3.31M vs. RSCI (-143.71K). ROMJF has higher revenues than RSCI: ROMJF (52.2M) vs RSCI (0).
ROMJFRSCIROMJF / RSCI
Capitalization28.7M14.3M201%
EBITDA3.31M-143.71K-2,304%
Gain YTD34.016-32.432-105%
P/E Ratio60.49N/A-
Revenue52.2M0-
Total Cash7.78MN/A-
Total Debt9.7MN/A-
FUNDAMENTALS RATINGS
ROMJF vs RSCI: Fundamental Ratings
ROMJF
RSCI
OUTLOOK RATING
1..100
643
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
37
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
92100
PRICE GROWTH RATING
1..100
3964
P/E GROWTH RATING
1..100
45100
SEASONALITY SCORE
1..100
950

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RSCI's Valuation (37) in the null industry is somewhat better than the same rating for ROMJF (70). This means that RSCI’s stock grew somewhat faster than ROMJF’s over the last 12 months.

RSCI's Profit vs Risk Rating (100) in the null industry is in the same range as ROMJF (100). This means that RSCI’s stock grew similarly to ROMJF’s over the last 12 months.

ROMJF's SMR Rating (92) in the null industry is in the same range as RSCI (100). This means that ROMJF’s stock grew similarly to RSCI’s over the last 12 months.

ROMJF's Price Growth Rating (39) in the null industry is in the same range as RSCI (64). This means that ROMJF’s stock grew similarly to RSCI’s over the last 12 months.

ROMJF's P/E Growth Rating (45) in the null industry is somewhat better than the same rating for RSCI (100). This means that ROMJF’s stock grew somewhat faster than RSCI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ROMJFRSCI
RSI
ODDS (%)
Bearish Trend 1 day ago
86%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
85%
N/A
Momentum
ODDS (%)
N/A
N/A
MACD
ODDS (%)
Bearish Trend 1 day ago
81%
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
57%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
67%
Bullish Trend 1 day ago
57%
Advances
ODDS (%)
Bullish Trend 4 days ago
71%
N/A
Declines
ODDS (%)
Bearish Trend 1 day ago
82%
N/A
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
81%
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
65%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ROMJF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NMTC0.790.06
+8.47%
NeuroOne Medical Technologies Corp
RNA50.361.89
+3.90%
Avidity Biosciences
LCTX1.220.02
+1.67%
Lineage Cell Therapeutics
DOLE13.560.16
+1.19%
Dole plc
SPOT707.193.34
+0.47%
Spotify Technology SA

ROMJF and

Correlation & Price change

A.I.dvisor tells us that ROMJF and SGIOF have been poorly correlated (+8% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ROMJF and SGIOF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ROMJF
1D Price
Change %
ROMJF100%
-4.79%
SGIOF - ROMJF
8%
Poorly correlated
N/A
SGIOY - ROMJF
8%
Poorly correlated
+2.98%
RSCI - ROMJF
5%
Poorly correlated
N/A
TEVJF - ROMJF
4%
Poorly correlated
N/A
PCLOF - ROMJF
3%
Poorly correlated
+5.13%
More

RSCI and

Correlation & Price change

A.I.dvisor tells us that RSCI and ETST have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RSCI and ETST's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RSCI
1D Price
Change %
RSCI100%
N/A
ETST - RSCI
22%
Poorly correlated
-0.74%
RAFA - RSCI
7%
Poorly correlated
N/A
SGIOF - RSCI
6%
Poorly correlated
N/A
TEVJF - RSCI
5%
Poorly correlated
N/A
SBFM - RSCI
5%
Poorly correlated
-5.24%
More